Get started
Author

Chris Barnes

Observed names: Barnes, Chris, C. Barnes, CHRIS BARNES
ORCID: 0000-0002-1528-1795
Observed ORCID: 0000-0002-1528-1795
OpenAlex ID: A5026644072
The Evolution of Physical and Technical Performance Parameters in the English Premier League
2014 · C. Barnes, D. Archer, et al. · International Journal of Sports Medicine · 973
Evolution of match performance parameters for various playing positions in the English Premier League
2014 · Michael Bush, Chris Barnes, et al. · Human Movement Science · 590
PDF
Match performance and physical capacity of players in the top three competitive standards of English professional soccer
2013 · Paul S. Bradley, Christopher Carling, et al. · Human Movement Science · 412
Tier-specific evolution of match performance characteristics in the English Premier League: it’s getting tougher at the top
2015 · Paul S. Bradley, David T. Archer, et al. · Journal of Sports Sciences · 211
PDF
Sub-maximal and maximal Yo–Yo intermittent endurance test level 2: heart rate response, reproducibility and application to elite soccer
2010 · Paul S. Bradley, M. Mohr, et al. · European Journal of Applied Physiology · 178
Positional interchanges influence the physical and technical match performance variables of elite soccer players
2015 · G. Schuth, G. Carr, et al. · Journal of Sports Sciences · 78
PDF
Perspectives of applied collaborative sport science research within professional team sports
2018 · James J. Malone, Liam D. Harper, et al. · European Journal of Sport Science · 69
A time-motion analysis of Paralympic football for athletes with cerebral palsy
2016 · Craig Boyd, Chris Barnes, et al. · International Journal of Sports Science & Coaching · 34
Longitudinal match performance characteristics of UK and non-UK players in the English Premier League
2016 · Michael Bush, David T Archer, et al. · Science and Medicine in Football · 26
PDF
Locomotor and collision characteristics by phases of play during the 2017 rugby league World Cup
2019 · Gordon Rennie, Nicholas Dalton-Barron, et al. · Science and Medicine in Football · 17
Mo1581 – Evaluation of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of Tak–954 in a Randomized, Placebo-Controlled Phase 1 Study
2019 · Richard Czerniak, Yinzhong Chen, et al. · Gastroenterology · 3
PDF
Efficacy of Revefenacin by Nebulization and Tiotropium by Handihaler in Subjects With Copd and Suboptimal Peak Inspiratory Flow Rates (pifr)
2018 · DONALD MAHLER, JILL OHAR, et al. · CHEST Journal · 3
752 - Efficacy and Safety of TAK-954 in Critically Ill Patients with Enteral Feeding Intolerance: A Randomized Phase 2A Clinical Trial
2018 · Marianne Chapman, Adam M. Deane, et al. · Gastroenterology · 3
Improvements in Health Status With Revefenacin, a Once-Daily Long-Acting Muscarinic Antagonist for Nebulization: Changes in St George’s Respiratory Questionnaire and COPD Assessment Test in Replicate 3-Month Studies
2017 · James Donohue, Srikanth Pendyala, et al. · CHEST Journal · 3
Trial in Progress: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial to Evaluate the Safety and Tolerability of a Nebulized Long-Acting Muscarinic Antagonist (Revefenacin) in Study Participants With COPD
2016 · Luis DeLaCruz, Srikanth Pendyala, et al. · CHEST Journal · 3
PDF
Predictors of Suboptimal Peak Inspiratory Flow Rate in Patients With Copd: Analyses From the Revefenacin Phase-3 Program
2019 · Jill Ohar, FCCP, et al. · CHEST Journal · 2
Efficacy of Revefenacin, a Long-acting Muscarinic Antagonist for Nebulized Therapy, in Copd Patients With Markers of More Severe Disease
2018 · JAMES DONOHUE, EDWARD KERWIN, et al. · CHEST Journal · 2
Cardiovascular Safety of Revefenacin for Nebulization: a Review of Randomized Controlled Trial Data
2018 · JAMES DONOHUE, GREGORY FELDMAN, et al. · CHEST Journal · 2
Safety and tolerability of bexotegrast in Phase 2 trials of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC)
2024 · Gregory Cosgrove, Richard Pencek, et al. · European Respiratory Journal · 1
Association Between Glucocorticoid Dose With Bmi and Glucocorticoid-related Comorbidities: Data From Tildacerfont Phase 2a Trials in Classic Congenital Adrenal Hyperplasia
2022 · Mimi Kim, Chris Barnes, et al. · Journal of the ASEAN Federation of Endocrine Societies · 1
PDF
Tolerability and Efficacy of Revefenacin When Administered With Formoterol Via Nebulization
2019 · Thomas Siler, Edmund Moran, et al. · CHEST Journal · 1
Defining Repeatability Limits for Measuring Peak Inspiratory Flow Rates in Clinical Trials
2019 · C. Barnes, D.A. Mahler, et al. · American Journal of Respiratory and Critical Care Medicine · 1
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD
2014 · David Bourdet, Chris Barnes, et al. · European Respiratory Journal · 1
Post-hoc Analysis of Biomarkers of Interstitial Lung Disease Progression in Participants With Idiopathic Pulmonary Fibrosis Receiving Bexotegrast Over 12-weeks in INTEGRIS-IPF
2024 · M. Decaris, R. Ahn, et al. · American Journal of Respiratory and Critical Care Medicine
2369. Clinical Experience With Telavancin for Treatment of Patients With Monomicrobial S. aureus Infections (Vancomycin MIC ≥1 μg/mL) From TOUR™
2018 · Micah Jacobs, Casmiar Nwaigwe, et al. · Open Forum Infectious Diseases
Works count: 29
Citation count: 2,614
H-index: 10
I10-index: 10
Year
Topic
Type